Indoramin

Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.

Indoramin

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C02CA02 (WHO)
Identifiers
IUPAC name N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide
CAS Number	26844-12-2 Y
PubChem CID	33625
IUPHAR/BPS	501
DrugBank	DB08950 Y
ChemSpider	31014 Y
UNII	0Z802HMY7H
KEGG	D04531 Y
ChEMBL	ChEMBL279516 Y
CompTox Dashboard (EPA)	DTXSID7048370
ECHA InfoCard	100.043.659
Chemical and physical data
Formula	C22H25N3O
Molar mass	347.462 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2[nH]c3)CC4
InChI InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) Y Key:JXZZEXZZKAWDSP-UHFFFAOYSA-N Y

It is an alpha-1 selective adrenoceptor antagonist^[1] with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).^[2]

It is commonly synthesized from tryptophol.^[3]

Dosage

Indoramin is commonly prescribed as 20 mg tablets when used in BPH.^[4]

Side Effects

Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.^[5]

Synthesis

Tryptamine and serotonin are naturally occurring indole ethylamino compounds with pronounced pharmacological activities. They have served as the inspiration for synthesis of numerous analogues.

One such study involved alkylation of 4-benzamidopyridine (2) with a bromoethyy compound (1) derived from tryptophol, to give a quaternary pyridinium salt (3); this intermediate was in turn hydrogenated with a Raney nickel catalyst to give indoramine.^[6][7]

Product withdrawal

On May 31, 2013, the French National Agency for the Safety of Medicines and Health Products (ANSM) concluded that the benefit/risk ratio of this product was unfavorable and withdrew Vidora's marketing authorization and recalled its batches from the market on June 3, 2013.^[8]